Effects of second and subsequent lines of chemotherapy for metastatic breast cancer

Clinical Breast Cancer

Volumn 15, Issue 1, 2015, Pages e55-e62

  Park, In Hae ^a   Lee, Keun Seok ^a   Ro, Jungsil ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemotherapy; Drug resistance; Metastatic breast cancer; Progression free survival; Response rate

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; DISEASE FREE SURVIVAL; MAINTENANCE CHEMOTHERAPY; METASTASIS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; SALVAGE THERAPY; STATISTICS AND NUMERICAL DATA; SURVIVAL;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; NEOPLASM METASTASIS; PALLIATIVE CARE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84920382676     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2014.09.001     Document Type: Article

References (24)

1. B. Ko, W. Noh, and S. Kang Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database J Breast Cancer 15 2012 393 400
2. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
3. P. Greenberg, G. Hortobagyi, and T. Smith Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer J Clin Oncol 14 1996 2197 2205
4. A. van Oosterom Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer Semin Oncol 22 6 suppl 13 1995 22 28
5. S. Verma, D. Miles, and L. Gianni Trastuzumab emtansine for HER2-positive advanced breast cancer N Engl J Med 367 2012 1783 1791
6. D. Bilancia, G. Rosati, and A. Dinota Lapatinib in breast cancer Ann Oncol 18 suppl 6 2007 vi26 vi30
7. J. Baselga, M. Campone, and M. Piccart Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 366 2012 520 529
8. F. André, and C. Zielinski Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents Ann Oncol 23 suppl 6 2012 vi46 vi51
9. K. Gogineni, and A. DeMichele Current approaches to the management of Her2-negative metastatic breast cancer Breast Cancer Res 14 2012 205
10. I. Park, J. Ro, and K. Lee Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer Invest New Drugs 28 2010 659 669
11. H. Stemmler, D. diGioia, and W. Freier Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer Br J Cancer 104 2011 1071 1078
12. P. Reichardt, G. Von Minckwitz, and P. Thuss-Patience Multicenter phase II study of oral capecitabine (Xeloda(")) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 2003 1227 1233
13. S. Chia, C. Speers, and Y. D'Yachkova The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer Cancer 110 2007 973 979
14. J. O'Shaughnessy Extending survival with chemotherapy in metastatic breast cancer Oncologist 10 suppl 3 2005 20 29
15. G. von Minckwitz, M. Untch, and J.-U. Blohmer Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 30 2012 1796 1804
16. A. Schott, and D. Hayes Defining the benefits of neoadjuvant chemotherapy for breast cancer J Clin Oncol 30 2012 1747 1749
17. K. Lee, J. Ro, and B.-H. Nam A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer Breast Cancer Res Treat 109 2008 481 489
18. S. Isakoff Triple-negative breast cancer: role of specific chemotherapy agents Cancer J 16 2010 53 61
19. O. Gluz, C. Liedtke, and N. Gottschalk Triple-negative breast cancer - current status and future directions Ann Oncol 20 2009 1913 1927
20. L. Carey, E. Dees, and L. Sawyer The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2007 2329 2334
21. A. Singh, and J. Settleman EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer Oncogene 29 2010 4741 4751
22. P. Tang, S. Bentzen, E. Chen, and L. Siu Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J Clin Oncol 25 2007 4562 4568
23. A. Gennari, M. Stockler, and M. Puntoni Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials J Clin Oncol 29 2011 2144 2149
24. T. Burzykowski, M. Buyse, and M. Piccart-Gebhart Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer J Clin Oncol 26 2008 1987 1992